INVO Bioscience (NASDAQ:INVO) Stock Price Down 11.6%

INVO Bioscience, Inc. (NASDAQ:INVO – Get Rating)’s stock price traded down 11.6% on Tuesday . The company traded as low as $0.52 and last traded at $0.53. 50,217 shares changed hands during trading, an increase of 47% from the average session volume of 34,162 shares. The stock had previously closed at $0.60.

INVO Bioscience Trading Down 11.6 %

The business has a 50-day moving average price of $0.58 and a two-hundred day moving average price of $0.88.

Institutional Investors Weigh In On INVO Bioscience

Several institutional investors have recently bought and sold shares of the stock. UBS Group AG grew its stake in INVO Bioscience by 99,137.6% in the 2nd quarter. UBS Group AG now owns 92,291 shares of the company’s stock valued at $59,000 after purchasing an additional 92,198 shares during the period. Ieq Capital LLC purchased a new position in shares of INVO Bioscience during the 3rd quarter valued at $53,000. Virtu Financial LLC lifted its position in shares of INVO Bioscience by 368.2% during the 2nd quarter. Virtu Financial LLC now owns 50,555 shares of the company’s stock valued at $33,000 after buying an additional 39,758 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of INVO Bioscience by 3.0% during the 3rd quarter. Vanguard Group Inc. now owns 367,390 shares of the company’s stock valued at $390,000 after buying an additional 10,653 shares during the last quarter. Institutional investors own 10.89% of the company’s stock.

INVO Bioscience Company Profile

(Get Rating)

IINVO BioScience, Inc is a fertility company. It focuses on the creation of treatment options for patients diagnosed with infertility. It offers a patented medical device that is used for infertility treatment under the name INVOcell. The company was founded by Kathleen Karloff and Claude Ranoux on January 5, 2007 and is headquartered in Sarasota, FL.